Mereo BioPharma (MREO) EBITDA Margin (2023 - 2025)
Mereo BioPharma's (MREO) quarterly EBITDA Margin came in at 2099.8% in Q2 2025, down 194.58% quarter-over-quarter from 712.8% in Q4 2023.
Powered by 
Analysis
Mereo BioPharma (MREO) EBITDA Margin (2023 - 2025) Analysis & Trends
Mereo BioPharma (MREO) has reported EBITDA Margin for 2 consecutive years, with 2099.8% the latest figure, recorded in Q2 2025.
- On a quarterly basis, EBITDA Margin changed N/A year-over-year to 2099.8% in Q2 2025; TTM through Jun 2026 was 6840.2%, a 242960.0% increase from a year earlier, with the FY2025 full-year figure at 8021.4%, changed N/A from the prior year.
- EBITDA Margin was 2099.8% for Q2 2025 at Mereo BioPharma, down from 712.8% in the prior quarter.
- Over five years, EBITDA Margin peaked at 9.01% in Q2 2023 and troughed at 2099.8% in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 34.95% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -133.21% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 37.40% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 30.15% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 32.54% |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -562.07% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 17.93% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | -23.56% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -25,380.93% |
| 10 | Mereo BioPharma | 38.92 Mn | 38.92 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2025 | -2,099.80% |
| Dec 31, 2023 | -712.80% |
| Jun 30, 2023 | -9.01% |